Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers. Cleave has amassed deep expertise and developed first-in-class drug candidates against novel targets in protein degradation pathways, including the ubiquitin proteasome and autophagy systems. Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs. Cleave is privately held and located in Burlingame, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/13 | $10,000,000 | Series A | ||
| 08/08/16 | $37,000,000 | Series B |
5AM Ventures Arcus Ventures Astellas Venture Management Celgene Corporation Clarus Ventures Nextech Invest OrbiMed Advisors Osage University Partners US Venture Partners | undisclosed |
